Garcinia

Garcinia (Garcinia cambogia / Garcinia gummi-gutta): A Comprehensive Reference

1. Identity: Botanical Names, Source, and Forms

1.1 Nomenclature and Taxonomy

The fruit rind of Garcinia gummi-gutta, commonly known as Garcinia cambogia, is the plant most widely associated with the commercially marketed dietary supplement. The name Garcinia cambogia persists in the scientific and popular literature as a recognized synonym, while Garcinia gummi-gutta (L.) N. Robson is now the accepted botanical name. It belongs to the family Clusiaceae (synonym: Guttiferae). Common names include Malabar tamarind, and in the regional vernacular of Kerala it is called kudampuli or kudam puli. In Ayurvedic tradition, it is known as Vrikshamla. It is also referred to in literature as brindleberry.

1.2 Natural Source and Botanical Description

Garcinia cambogia is a tree native to India and Southeast Asia, where it is commonly found in evergreen forests. It is a small to medium-sized tree, usually 5–7 meters tall, with glossy, round leaves that grow opposite each other. The fruit resembles a pumpkin in shape but is much smaller, averaging 3–7 centimeters in diameter, and turns bright yellow or pale green when ripe. The rind contains most of the bioactive compounds, notably hydroxycitric acid.

Hydroxycitric acid, both in free acid and lactone forms, is present in the fruit rind of Garcinia species including Garcinia cambogia, Garcinia atroviridis, and Garcinia indica, which are commercially available in India. (-)-Hydroxycitric acid (HCA) is a principal constituent (10–30%) of the dried fruit rind of Garcinia cambogia. The dried rind was used for centuries throughout Southeast Asia as a food preservative.

1.3 Preparations and Commercial Forms

Traditionally, the fruit is considered too sour or acidic to be consumed fresh and is most often incorporated into recipes as dried rinds or processed extracts. When dried, the rind becomes dark brown and is commonly used in curries, pickles, and traditional digestive preparations in Kerala and coastal Karnataka.

In the modern supplement market, the compound of primary interest in Garcinia supplements is hydroxycitric acid (HCA), which occurs naturally in the dried fruit rind at concentrations up to 30% by weight. Commercial Garcinia extracts are typically standardized to contain 50–60% HCA. G. cambogia peel supplements contain 20–60% HCA, which may be the reason for their weight loss properties. Supplements are sold principally as capsules and tablets. Because HCA is typically bound to calcium and potassium salts, Garcinia supplements at typical daily doses can deliver meaningful amounts of these minerals — for example, a daily dose of 4,500 mg of one proprietary preparation (SuperCitrimax) would be expected to provide approximately 720 mg of potassium and 495 mg of calcium.

2. Traditional and Historical Use

2.1 Culinary Use

The fruit rind of Garcinia gummi-gutta is extensively used traditionally as a flavourant in fish curries due to its sharp sour taste. This culinary practice is particularly documented in coastal South India (Kerala and Karnataka) and parts of Southeast Asia, where the dried rind serves as a souring agent analogous to tamarind.

2.2 Folk and Ethnobotanical Medicine

Additional ethnobotanical uses include its use as a digestive and a traditional remedy to treat bowel complaints, intestinal parasites, and rheumatism. The fruit has been used as a tea in folk medicine for inflammation and stomach complaints, while the fruit rind has a history of traditional use as a food preservative.

Traditionally used in South Indian and Southeast Asian cuisines, Vrikshamla also holds a place in classical Ayurvedic texts as a digestive, carminative, and fat-reducing herb. The fruit's active compound, HCA, has been extensively studied for its potential to support lipid metabolism and suppress fat accumulation. In Ayurvedic texts, Vrikshamla is noted for its sour and astringent properties, which help regulate digestion, appetite, and Agni (digestive fire). It is considered to help balance Kapha and Pitta doshas, especially in the context of sluggish metabolism and excess accumulation.

The fruit has a long history in traditional medicine — used as a tea for inflammation and stomach complaints — and its rind has been used as a food preservative and culinary ingredient throughout the region. Early historical documentation of its medicinal use places it squarely within the Ayurvedic and regional folk medicine traditions of South and Southeast Asia, though it does not feature as prominently in classical Sanskrit texts as some other major Ayurvedic herbs such as turmeric or ashwagandha.

3. Key Constituents and Active Compounds

3.1 Principal Organic Acid: Hydroxycitric Acid (HCA)

The principal acid in the highly acidic fruits of Garcinia cambogia has been identified as (-)-hydroxycitric acid. HCA is an α-, β-dihydroxytricarboxylic acid that is a potent competitive inhibitor of adenosine triphosphate (ATP) citrate lyase, which is a key enzyme in the synthesis of fatty acids, cholesterol, and triglycerides. ATP-citrate lyase cleaves citrate into oxaloacetate and acetyl-CoA, so HCA eventually limits the number of acetyl-CoA molecules available for fatty acid synthesis.

A second proposed mechanism relates to appetite modulation via the serotonergic system. It has been demonstrated that HCA enhances the brain release of serotonin, which could reduce appetite and control conditions related to low serotonin levels including depression, migraine, insomnia, and headaches. A third mechanism involves downstream effects on fat oxidation: HCA may bring about an anorectic effect by reducing acetyl-CoA, subsequently decreasing malonyl-CoA levels, and thereby reducing negative feedback on carnitine acyltransferase (CPT-1), potentially increasing fat oxidation.

3.2 Secondary Metabolites

Phytochemical studies of various plant parts have revealed the presence of mainly xanthones (e.g., carbogiol) and benzophenones (e.g., garcinol), together with organic acids (e.g., HCA) and amino acids (e.g., gamma-aminobutyric acid). Preliminary phytochemical studies revealed the presence of alkaloids, flavonoids, phenolic compounds, saponins, tannins, carbohydrates, and proteins.

Phytochemical analysis has revealed the presence of HCA as the primary organic acid in this plant, along with secondary metabolites such as benzophenones (i.e., garcinol and guttiferones [I, J, K, M, and N]), xanthones, and flavonoids.

A new xanthone, garbogiol, was isolated from the root of Garcinia cambogia; a known xanthone (rheediaxanthone A) and two known benzophenones (garcinol and isogarcinol) were obtained from the bark. Several studies have revealed that garcinol exerts a wide range of biological potentials, including anti-inflammatory, antitumor, antioxidant, antimicrobial, and neuroprotective effects. Emergent studies suggest that garcinol may be a useful anti-cancer agent and a pleiotropic agent that modulates key regulatory pathways for cell signals. However, much of this research is preclinical.

3.3 Mechanistic Summary

Four different mechanisms have been proposed for the antiobesity effect of HCA: (1) regulation of serotonin, suppression of food intake, (2) decreased lipogenesis (storage in adipose tissue), (3) increased β-oxidation of fatty acids, and (4) effects on satiety hormones such as leptin. HCA is a derivative of citric acid, marketed as a weight loss supplement. Some experts believe it works by inhibiting the enzyme citrate lyase, interfering with the conversion of unused carbohydrates into fat. Although HCA does have this effect in laboratory conditions, it is unproven whether it does so once inside the body. Other experts suggest HCA affects other enzymes involved in carbohydrate metabolism, such as pancreatic alpha-amylase and intestinal alpha-glucosidase.

4. Scientific Evidence by Area of Use

4.1 Body Weight and Obesity

Evidence overview: The largest body of human clinical evidence on Garcinia cambogia / HCA is focused on body weight and body composition. Multiple systematic reviews and meta-analyses have been conducted.

A landmark 2011 systematic review and meta-analysis by Onakpoya and colleagues, published in the Journal of Obesity, is the most widely cited analysis. The aim was to examine the efficacy of Garcinia extract / HCA as a weight reduction agent using data from randomized clinical trials (RCTs). Electronic and non-electronic searches were conducted with no restrictions in language or time; two independent reviewers extracted data. Twenty-three eligible trials were identified and twelve were included; nine trials provided data suitable for statistical pooling. The meta-analysis revealed a small, statistically significant difference in weight loss favouring HCA over placebo (mean difference: −0.88 kg; 95% CI: −1.75, −0.00). However, the evidence from RCTs suggests that Garcinia extracts/HCA generate weight loss in the short term; however, the magnitude of this effect is small, is no longer statistically significant when only rigorous RCTs are considered, and its clinical relevance seems questionable. Furthermore, the methodological quality of most of the identified studies is poor, and most studies are of short duration, preventing firm conclusions about the effects of HCA on body weight.

A more recent 2020 dose-response meta-analysis (Golzarand et al., Complementary Therapies in Medicine) pooling eight RCTs with 530 subjects found somewhat larger effects: Garcinia cambogia supplement significantly reduced weight by −1.34 kg (95% CI: −2.62 to −0.07, P = 0.03), BMI by −0.99 kg/m² (95% CI: −1.48 to −0.49, P < 0.001), percentage of fat mass by −0.42% (95% CI: −0.77 to −0.06, P = 0.02), and waist circumference by −4.16 cm (95% CI: −7.83 to −0.49, P = 0.02) compared with placebo. Dose-response analysis revealed a nonlinear association between Garcinia cambogia dosage and changes in body weight and BMI.

A scoping review focusing on clinically significant thresholds reached a more negative conclusion: double-blinded RCTs and systematic reviews of RCTs were included in the analysis; of the 14 included studies, all failed to demonstrate a clinically significant decrease in weight or BMI.

Preclinical studies using rodent models have confirmed body weight reduction, appetite suppression, and food intake reduction effects of HCA in rats. Clinically, however, HCA has failed to perform as well. Several factors that may contribute include that ATP citrate lyase might be important only at very high-carbohydrate diets, a type that most studies did not prescribe. Additionally, a high-fiber diet can bind to HCA and block it, reducing its efficacy. HCA and G. cambogia exert potential effects in weight management, but clinical studies have yet to prove optimal conditions for HCA to be effective.

A specific double-blind, randomized, placebo-controlled trial examined visceral fat as a primary endpoint: subjects aged 20 to 65 years with a visceral fat area >90 cm² were enrolled, and subjects were randomly assigned to receive treatment for 12 weeks with G. cambogia (containing 1,000 mg of HCA per day) or placebo. Subjects were instructed to take 3 tablets 30 minutes before each meal (9 tablets/day), with a total daily dose of 1,667.25 mg of G. cambogia extract containing 1,000 mg of HCA.

Evidence strength (weight loss): Overall, the evidence is mixed and weak-to-modest. While statistically significant effects have been observed in some meta-analyses, the absolute magnitude of weight loss is small, many constituent studies have methodological limitations, and clinical significance remains uncertain. NCCIH concludes that it is unclear whether garcinia cambogia products help with weight loss; some evidence suggests a modest effect, while other evidence shows no effect, and more research is needed to confirm any effects.

4.2 Appetite and Satiety

The appetite-suppressing mechanism of HCA via serotonin modulation has been widely proposed, but human evidence is inconsistent. In one double-blind, placebo-controlled trial, the treatment group lost significantly more weight (3.7 ± 3.1 kg vs. 2.4 ± 2.9 kg), but HCA did not affect appetite, and the study did not support a satiety effect of HCA. Contradictory results on satiation and appetite suppression have been obtained; Kovacs et al. (2001) observed no appetite-suppressant effect after 2-week supplementation of HCA alone or combined with medium-chain triglycerides.

Evidence strength (appetite): Preliminary and inconsistent. A serotonin-mediated appetite mechanism is biologically plausible and supported by some animal and ex-vivo data, but has not been convincingly demonstrated in adequately powered human trials.

4.3 Lipid Profiles (Cholesterol and Triglycerides)

Laboratory studies on human cells and animal studies suggested Garcinia cambogia reduced cell synthesis of lipids and increased degradation of cholesterol, but human trials have been contradictory. A 2008 study reported a significant reduction in total cholesterol and LDL-cholesterol when Garcinia cambogia extract was combined with Amorphophallus konjac; however, no effect was seen on triglyceride or glucose levels. No effects on triglycerides have been reported across the broader literature. Based on the available evidence, Garcinia cambogia is unlikely to have an effect on blood glucose or cholesterol levels, and does not appear beneficial for people with diabetes.

Evidence strength (lipids): Weak. Results from animal and in-vitro models are more consistent, but human trial data are contradictory and generally do not support clinically meaningful lipid-lowering effects.

4.4 Blood Glucose and Insulin Sensitivity

Preclinical investigation has found antidiabetic and antihyperlipidemic activity of G. cambogia rind extract in animal models. The antidiabetic and antihyperlipidemic effects of ethanol extract of G. cambogia fruit rind have been evaluated in a streptozotocin-nicotinamide-induced diabetic Wistar rat model, showing measurable effects. However, most trials have not shown Garcinia cambogia to have an effect on blood sugars or insulin control in humans; one trial reported a lowering in healthy non-diabetic subjects while another reported an increase in fasting blood sugar levels in overweight individuals.

Evidence strength (blood glucose): Preclinical findings are promising; human evidence is sparse, inconsistent, and insufficient to support clinical use for glycemic management.

4.5 Leptin and Adipokines

Garcinia cambogia, which contains the main compound HCA, is one of the natural-source products that can affect leptin levels and, as a result, plays a role in appetite control. There are contradictory results about the effect of GC on leptin; for instance, a study showed that GC increases serum leptin levels and suppresses appetite.

Evidence strength (leptin/adipokines): Preliminary. Contradictory data from RCTs; a systematic review and meta-analysis of RCTs on this specific outcome has been conducted (2024), but results remain inconclusive.

4.6 Anti-Inflammatory, Antimicrobial, Anticancer, and Other Activities

The crude extract or constituents from the plant also exerted hypolipidaemic, antidiabetic, anti-inflammatory, anticancer, anthelmintic, anticholinesterase, and hepatoprotective activities in in vitro and in vivo models. These phytochemicals exert several important functions, including antioxidant, antimicrobial, antidiabetic, immunomodulatory, and anti-inflammatory properties.

With respect to the benzophenone garcinol specifically, its activities include inhibition of histone acetyltransferases (HATs), a discovery that has been followed by research into regulation of oncogenic microRNAs and modulation of signaling pathways critical to tumor progression. These findings are derived from cell-line and animal experiments.

Evidence strength (anti-inflammatory, antimicrobial, anticancer): These findings are based exclusively or predominantly on in-vitro and animal studies. No human clinical trials are available to evaluate these endpoints for Garcinia cambogia or its isolated constituents. Clinical trial reports that are available predominantly focus on the anti-obesity activity of G. cambogia/HCA supplements. All other biological activities remain at the preclinical stage.

5. Body Systems and Health Areas Associated with Garcinia

• Metabolic / Adipose tissue: Inhibition of de novo lipogenesis via ATP-citrate lyase; potential effects on body weight, visceral fat, and fat mass.
• Gastrointestinal system: Traditional use as a digestive agent; folk use for bowel complaints, intestinal parasites, and stomach discomfort. The fruit has been used as a tea in folk medicine for inflammation and stomach complaints.
• Central nervous system / Appetite regulation: Proposed serotonergic activity of HCA affecting satiety, mood, and appetite signaling.
• Hepatic system: Paradoxically, while preclinical data suggest possible hepatoprotective properties of some extracts, clinical reports have documented hepatotoxicity. See Safety section.
• Cardiovascular / Lipid metabolism: Extracts include xanthones, benzophenones, and organic acids — most importantly hydroxycitric acid — which have antiobesity, hypolipidemic, antioxidant, anti-inflammatory, and antiprotozoal activities. Human evidence for cardiovascular endpoints is weak.
• Endocrine system: Potential modulation of leptin, adiponectin, and insulin sensitivity reported in some studies, primarily animal and small-scale human trials.

6. Dosage Forms and Dosages Reported in Studies

In one trial, participants took extract (60% HCA) 1 hour before lunch, 1 hour before dinner, and 2 hours after dinner. Each dose was 500 mg extract, for a daily total of 1,500 mg extract containing 900 mg HCA.

In a 12-week double-blind, randomized, placebo-controlled trial, subjects were randomly assigned to receive G. cambogia containing 1,000 mg of HCA per day or placebo. Subjects were instructed to take 3 tablets 30 minutes before each meal (9 tablets/day), with a total daily dose of 1,667.25 mg of G. cambogia extract containing 1,000 mg of HCA.

A long-term study examined the effects on body fat accumulation in humans who were pre-obese or obese class 1 (BMI from 25 to 35 kg/m²). A total of 40 subjects were randomized to either a G. cambogia group (n=20, 1,000 mg of HCA per day) or a placebo group (n=20). The treatment period was 8 weeks.

One supplement product involved in a clinical safety case listed the following active ingredients per serving: G. cambogia (fruit rind) extract (60% HCA) 1,000 mg, chromium 200 μg, potassium 50 μg, and calcium 50 μg; serving size was two capsules.

In one study, no adverse effects were observed at a dose of 2,800 mg/day, which has been suggested as a safe limit. The non-observed adverse effect level (NOAEL) has been studied in animal models: diets containing doses equivalent to 778 and 1,244 mg HCA/kg body weight/day caused potent testicular atrophy and toxicity in male Zucker obese rats, whereas the dose of 389 mg HCA/kg body weight/day or less did not. Accordingly, 389 mg HCA/kg body weight/day was deemed the no observed adverse effect level (NOAEL). This rat-derived NOAEL does not directly translate to human dosing recommendations.

7. Safety Considerations and Drug Interactions

7.1 Hepatotoxicity

The most clinically significant safety concern associated with Garcinia cambogia products is drug-induced liver injury (DILI). More than 200 adverse events of liver injury resulting from Garcinia consumption have been identified. A total of 34 case reports of Garcinia hepatotoxicity indicated one death and nine liver transplants, with 17 cases receiving CIOMS/RUCAM scores that indicated possible to highly probable causality due to Garcinia dietary supplements.

Clinical case reports of liver injury associated with Garcinia dietary supplements prompted the United States Pharmacopeia (USP) to revise the USP Garcinia family of dietary ingredient monographs to include a cautionary statement regarding potential risk of liver damage.

Garcinia toxicity was consistent with drug-induced liver injury and included elevated serum liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase with a high ratio of ALT to alkaline phosphatase. Patients typically present with fatigue, nausea, elevations in serum aminotransferase levels, and jaundice 1 to 4 weeks after starting the product, although the latency to onset has been longer (3 to 12 months) in some cases. The pattern of enzyme elevations is hepatocellular, and immune features are not common.

There have been at least a dozen reports of Garcinia-induced liver injury in individuals taking multi-ingredient dietary supplements (MIDS) that contain Garcinia cambogia. In some instances, other known or suspected hepatotoxins were present in the MIDS products. More recently, cases of acute liver injury have been identified in persons taking a product labelled as having Garcinia cambogia alone. The frequency of hepatic adverse reactions to Garcinia cambogia is not known but is likely uncommon and in less than 1:10,000 persons.

Reactions ranged from mild, symptomatic hepatitis to, in a few instances, acute liver failure requiring liver transplant. A large number of G. cambogia/HCA dietary supplements for weight management are being sold, although the possible toxicity associated with their regular use has raised concerns. In most cases, complaints have been related to multicomponent formulations, and at this stage G. cambogia has not been confirmed as the potentially toxic culprit in all cases.

Research into mechanisms has suggested that herb-drug interactions may potentiate liver injury. The combination of G. cambogia with montelukast (an anti-asthmatic drug known to be hepatotoxic) greatly reduced cell viability, increased intracellular ROS levels, and affected cytoplasmic Nrf2 expression, suggesting an impairment of antioxidant and cytoprotective defenses.

NCCIH states plainly that it may be unsafe to consume garcinia cambogia products, including multi-ingredient products containing garcinia cambogia extract. Several cases of liver damage have been reported; some of these cases were severe, but this appears to be uncommon.

7.2 Serotonin Syndrome / Serotonergic Interactions

HCA has been shown to act as a selective serotonin reuptake inhibitor, increasing serotonin levels and serotonin toxicity. This is the case of a 35-year-old woman on stable treatment with escitalopram (an SSRI) for one year, who developed tremors, flushing, and diaphoresis after using a G. cambogia extract (60% HCA) supplement for weight loss during the last 2–3 months. She was diagnosed with serotonergic syndrome and treatment with escitalopram was stopped.

In studies, statistically significant differences in serotonin levels were noted between 4 and 8 weeks in the groups receiving HCA. Thus, there appears to be a delay in the buildup of intrinsic serotonin. A case series describes 3 stable patients whose manias emerged during use of Garcinia cambogia. The putative mediator of G. cambogia's weight loss effect is HCA, a substance with demonstrated serotonergic activity in animals and humans. There are known case reports suggesting HCA-containing weight loss supplements may contain psychoactive serotonergic properties.

There is limited evidence that HCA may increase endogenous serotonin concentrations. However, the clinical case reports indicate this pharmacological property is real enough to produce serotonin toxicity when combined with serotonergic drugs.

7.3 Interactions with Other Medications

Regarding antidepressants, Garcinia might increase a brain chemical called serotonin; some medications for depression also increase serotonin. Taking Garcinia along with these medications for depression might increase serotonin too much and cause serious side effects including heart problems, shivering, and anxiety.

With respect to anticoagulants, a review carried out on the concomitant use of plants with warfarin treatment found that between 2016 and 2021, 114 medicinal plants were noted to interact with warfarin. Garcinia is among the herbs flagged in pharmacovigilance literature for potential anticoagulant interactions, though direct mechanistic human evidence is limited.

Gastrointestinal adverse events were twice as common in the HCA group compared with placebo in one included systematic review study.

7.4 Reproductive Toxicity (Animal Data)

The highest dose of HCA-containing Garcinia cambogia (154 mmol HCA/kg diet) showed significant suppression of epididymal fat accumulation in developing male Zucker obese rats; however, diets containing doses equivalent to 778 and 1,244 mg HCA/kg body weight/day caused potent testicular atrophy and toxicity, whereas the dose of 389 mg HCA/kg body weight/day or less did not. This finding is from an animal model and its relevance to human supplementation at typical doses is uncertain.

7.5 Product Quality and Multicomponent Formulations

Garcinia cambogia has recently grown in popularity as a herbal and dietary supplement. Although herbal and dietary supplements might be publicised as safe, they account for 20% of drug-induced liver injury. A further complexity in safety evaluation is that many commercial products combine Garcinia cambogia with other ingredients, making attribution of specific adverse effects to Garcinia alone difficult in some reports.

References

• Onakpoya I, Hung SK, Perry R, Wider B, Ernst E. The Use of Garcinia Extract (Hydroxycitric Acid) as a Weight loss Supplement: A Systematic Review and Meta-Analysis of Randomised Clinical Trials. Journal of Obesity. 2011. PMC3010674.
• Golzarand M, Omidian M, Toolabi K. Effect of Garcinia cambogia supplement on obesity indices: A systematic review and dose-response meta-analysis. Complementary Therapies in Medicine. 2020. PubMed 32951714.
• Hayamizu K, et al. Effects of Garcinia cambogia (Hydroxycitric Acid) on visceral fat accumulation: a double-blind, randomized, placebo-controlled trial. Current Therapeutic Research. 2003. PMC4053034.
• Semwal RB, Semwal DK, Vermaak I, Viljoen A. A comprehensive scientific overview of Garcinia cambogia. Fitoterapia. 2015. ScienceDirect.
• Hashem MM, et al. Recent Advances in Garcinia cambogia Nutraceuticals in Relation to Its Hydroxy Citric Acid Level. ACS Omega. 2022.
• National Center for Complementary and Integrative Health (NCCIH). Garcinia Cambogia: Usefulness and Safety.
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Garcinia Cambogia. NCBI Bookshelf.
• Hepatotoxicity of dietary supplements containing Garcinia gummi-gutta (L.) N. Robson. Pharmaceutical Biology. 2025.
• Lopez AM, Kornegay J, Hendrickson RG. Serotonin Toxicity Associated with Garcinia cambogia Over-the-counter Supplement. Journal of Medical Toxicology. 2014. PMC4252288.
• Acute Severe Liver Injury Related to Long-Term Garcinia cambogia Intake. PMC7423904.
• Hepatotoxicity associated with Garcinia cambogia: A case report. PMC6856022.
• Interaction of Garcinia cambogia and Drugs as a Possible Mechanism of Liver Injury: The Case of Montelukast. Antioxidants. 2023. MDPI.
• Effects of Hydroxycitric Acid Supplementation on Body Composition, Obesity Indices, Appetite, Leptin, and Adiponectin of Women with NAFLD. PMC10356186.
• Garcinia cambogia water extract alleviates insulin resistance and hepatic lipid accumulation in mice fed a high-fat diet. PMC10084504.
• Chuah LO, et al. Updates on Antiobesity Effect of Garcinia Origin (−)-HCA. Evidence-Based Complementary and Alternative Medicine. 2013.
• High dose of Garcinia cambogia is effective in suppressing fat accumulation in developing male Zucker obese rats, but highly toxic to the testis. PubMed 15680676.
• Efficacy of Garcinia Cambogia (HCA) in Reducing Body Weight in Overweight and Obese Adults: A Scoping Review. Auctores Online.
• Mania Induced by Garcinia cambogia: A Case Series. Primary Care Companion for CNS Disorders. 2021.
• Dietary Supplements for Weight Loss and Drug Interactions. PMC11678256.
• The effects of Garcinia cambogia (hydroxycitric acid) on serum leptin concentrations: A systematic review and meta-analysis of randomized controlled trials. Phytotherapy Research. 2024.
• Anti-Inflammatory Effect of Garcinol via Modulating NF-κB Signaling Pathway. PMC9918937.
• Garcinol as an Epigenetic Modulator: Mechanisms of Anti-Cancer Activity and Therapeutic Potential. International Journal of Molecular Sciences. 2025.
• Committee on Toxicity (COT). Drug interactions — Garcinia cambogia. UK Food Standards Agency.
• Garcinia cambogia Phenolics as Potent Anti-COVID-19 Agents: Phytochemical Profiling, Biological Activities, and Molecular Docking. PMC9572397.
• Nutraceutical, functional, and therapeutic properties of Garcinia cambogia: a review. International Journal of Food Properties. 2023.